MCC
GALT icon

Money Concepts Capital’s Galectin Therapeutics GALT Stock Holding History

Money Concepts Capital’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$1.13K – 1427
2022
Q4 		$1.13K Buy
+1,000
New +$1.33K ﹤0.01% 2849
2022
Q2 		– Sell
-1,000
Closed -$2K – 1893
2022
Q1 		$2K Buy
+1,000
New +$1.94K ﹤0.01% 2446

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Money Concepts Capital's GALT Position: Q1 2023 in Review

Money Concepts Capital sold out of Galectin Therapeutics (GALT) in Q1 2023, closing a stake of 1,000 shares — an estimated $1.13K sold.

Money Concepts Capital first reported a position in GALT in Q1 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 60 funds tracked by Wall St. Rank hold GALT as of Q1 2023.

  • Money Concepts Capital reported no remaining Galectin Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 1,000 Galectin Therapeutics shares in Q1 2023, an estimated $1.13K.
  • Money Concepts Capital first reported a position in Galectin Therapeutics in Q1 2022 and held it in 2 quarters.
  • Money Concepts Capital's Galectin Therapeutics position peaked at $2K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.